(Q38006032)

English

Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections

scientific article published on June 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections. (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

0 references

Pseudomonas aeruginosa

0 references

cystic fibrosis

0 references

4

object named as

Niels Høiby

0 references

1

object named as

Oana Ciofu

0 references

Lotte F Mandsberg

2

object named as

Lotte F Mandsberg

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

author name string

Hengzhuang Wang

3

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

publication date

1 June 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

FEMS Immunology and Medical Microbiology

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

65

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

215-225

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Constitutive high expression of chromosomal beta-lactamase in Pseudomonas aeruginosa caused by a new insertion sequence (IS1669) located in ampD

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and beta-lactamase and alginate production.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Endogenous oxidative stress produces diversity and adaptability in biofilm communities

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

The metabolically active subpopulation in Pseudomonas aeruginosa biofilms survives exposure to membrane-targeting antimicrobials via distinct molecular mechanisms

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Genetic adaptation of Pseudomonas aeruginosa during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in mucA and/or lasR mutants

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Role of mutation in Pseudomonas aeruginosa biofilm development.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Multidrug efflux pumps: expression patterns and contribution to antibiotic resistance in Pseudomonas aeruginosa biofilms.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Early intervention and prevention of lung disease in cystic fibrosis: a European consensus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Increased mutability of Pseudomonas aeruginosa in biofilms

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Survival strategies of infectious biofilms

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Molecular basis of azithromycin-resistant Pseudomonas aeruginosa biofilms

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed beta-lactamase producing strains

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

High-level beta-lactamase activity in sputum samples from cystic fibrosis patients during antipseudomonal treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Differentiation and distribution of colistin- and sodium dodecyl sulfate-tolerant cells in Pseudomonas aeruginosa biofilms.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Pseudomonas aeruginosa biofilm infections in cystic fibrosis: insights into pathogenic processes and treatment strategies.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Pharmacokinetics/pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Aminoglycoside antibiotics induce bacterial biofilm formation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Antibiotic resistance of bacterial biofilms

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Chromosomal mechanisms of aminoglycoside resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

A common mechanism of cellular death induced by bactericidal antibiotics

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Polymorphonuclear leucocytes consume oxygen in sputum from chronic Pseudomonas aeruginosa pneumonia in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Inactivation of efflux pumps abolishes bacterial biofilm formation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Heterogeneity of biofilms formed by nonmucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Dynamics of mutator and antibiotic-resistant populations in a pharmacokinetic/pharmacodynamic model of Pseudomonas aeruginosa biofilm treatment.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Development of antibiotic resistance and up-regulation of the antimutator gene pfpI in mutator Pseudomonas aeruginosa due to inactivation of two DNA oxidative repair genes (mutY, mutM).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic infections

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Antagonistic interactions of Pseudomonas aeruginosa antibiotic resistance mechanisms in planktonic but not biofilm growth.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

The penetration of antibiotics into aggregates of mucoid and non-mucoid Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Role of alginate and its O acetylation in formation of Pseudomonas aeruginosa microcolonies and biofilms

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Characterization of the GO system of Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Pharmacokinetics of inhaled colistin in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Early adaptive developments of Pseudomonas aeruginosa after the transition from life in the environment to persistent colonization in the airways of human cystic fibrosis hosts

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

In vivo pharmacodynamic activity of daptomycin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Extracellular DNA Required for Bacterial Biofilm Formation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Heterogeneity in Pseudomonas aeruginosa biofilms includes expression of ribosome hibernation factors in the antibiotic-tolerant subpopulation and hypoxia-induced stress response in the metabolically active population

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

In situ growth rates and biofilm development of Pseudomonas aeruginosa populations in chronic lung infections

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Evolutionary dynamics of bacteria in a human host environment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Mucoid Pseudomonas aeruginosa isolates maintain the biofilm formation capacity and the gene expression profiles during the chronic lung infection of CF patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa

1 reference

https://api.crossref.org/works/10.1111%2FJ.1574-695X.2012.00983.X

21 January 2018

Identifiers

10.1111/J.1574-695X.2012.00983.X

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38006032&oldid=2177567677"